Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 7/20 | 0.60 |
| ▸ | BCHE | P06276 | 2/20 | 0.48 |
| ▸ | ACHE | P22303 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TNF | P01375 | 2/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.42 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23447164 | 0.91 | TLR2 (0.52) | TLR2BCHEACHEMDM2 | |
| SCHEMBL16048760 | 0.90 | TLR2 (0.51) | TLR2BCHEACHEKMT2AMDM2 | |
| SCHEMBL16048758 | 0.90 | TLR2 (0.51) | TLR2BCHEACHEKMT2AMDM2 | |
| SCHEMBL27153081 | 0.89 | TLR2 (0.50) | TLR2KMT2AMDM2 | |
| SCHEMBL30771460 | 0.89 | TLR2 (0.50) | TLR2KMT2AMDM2 | |
| SCHEMBL30771405 | 0.89 | TLR2 (0.50) | TLR2KMT2AMDM2 | |
| SCHEMBL31296168 | 0.89 | TLR2 (0.50) | TLR2KMT2AMDM2 | |
| SCHEMBL30771499 | 0.89 | TLR2 (0.50) | TLR2KMT2AMDM2 | |
| SCHEMBL25845385 | 0.89 | TLR2 (0.54) | TLR2BCHEACHEKMT2AMDM2 | |
| SCHEMBL26044431 | 0.89 | TLR2 (0.56) | TLR2BCHEACHEKMT2ATNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | Arrowhead Pharmaceuticals, Inc. | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | MUSK, MYLK2, TNNC1 | TLR2 3599/4885BCHE 3578/4885ACHE 3139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.